Posts Tagged ‘additional’
SciClone And Sigma-Tau Announce Additional Positive Results In Clinical Study Examining ZADAXIN’s Ability To Enhance Response To H1N1 Vaccine
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…
Training auscultatory skills: computer simulated heart sounds or additional bedside training? A randomized trial on third-year medical students
Background:The present study compares the value of additional use of computer simulated heart sounds, to conventional bedside auscultation training, on the cardiac auscultation skills of 3rd year medical students at Oslo University Medical School.Methods:In addition to their usual curriculum courses, groups of seven students each were randomized to receive four hours of additional auscultation training either employing a computer simulator system or adding on more conventional bedside training. Cardiac auscultation skills were afterwards tested using live patients. Each student gave a written description of the auscultation findings in four selected patients, and was rewarded from 0-10 points for each patient. Differences between the two study groups were evaluated using student’s t-test.Results:At the auscultation test no significant difference in mean score was found between the students who had used additional computer based sound simulation compared to additional bedside training.Conclusions:Students at an early stage of their cardiology training demonstrated equal performance of cardiac auscultation whether they had received an additional short auscultation course based on computer simulated training, or had had additional bedside training.
ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza
ImmuneRegen BioSciences Inc.?, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced additional positive results from a recent study that evaluated its lead anti-influenza drug, Homspera?, in ferrets…
FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC. As with the four previous H1N1 influenza vaccines licensed by the FDA on Sept.
Three Additional Alabama Deaths Linked To 2009 H1N1 Influenza
The Alabama Department of Public Health has been notified in the past week about the deaths of three individuals: a man in his 60s from Talladega County, a woman in her 50s from Madison County, and a female in her 70s from Jackson County. Specimens showed they tested positive for 2009 H1N1 influenza. Previous deaths of persons positive for H1N1 influenza have occurred this year in Bullock, Dale, Houston, Jackson, Jefferson, Macon, Montgomery and Russell counties.
Additional Alabama Death Linked To 2009 H1N1 Influenza
The Alabama Department of Public Health has been notified about the death of a woman in her 50s who resides in Dale County. Specimens showed she tested positive for 2009 H1N1 influenza. The widespread incidence of 2009 H1N1 influenza in Alabama and the eight known deaths in the state serve as reminder of the need for everyone to take steps to prevent transmission of disease and to be immunized for both seasonal and H1N1 influenza when vaccine becomes available.
Additional Alabama Deaths Linked To 2009 H1N1 Influenza
The Alabama Department of Public Health has been informed that a resident of Bullock County and a resident of Macon County have died. The men, one in his 40s and one in his 50s, died at a Montgomery hospital. Specimens from both men tested positive for H1N1 influenza. These deaths serve as reminder of the need for everyone to take additional precautions because of the early onset of influenza in Alabama.
HHS Purchases Additional H1N1 Vaccine Ingredients
HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus. “We recognize that preparedness is shared responsibility between federal, tribal, state, local governments, private organizations and individuals.
Find Additional Funding For ‘Flu – British Medical Association
Commenting today on the Finance Minister’s decision that he would not allocate the necessary £55 million funding to combat the swine flu pandemic, Dr Brian Patterson, Chairman of the BMA’s Northern Ireland Council said, “Tackling the pandemic caused by the H1N1 virus is a major public health challenge for Northern Ireland that requires a united response from the Northern Ireland Assembly leadership.
King Provides Additional Information On The REMOXY(R) NDA Resubmission Plan
King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY(R) New Drug Application (NDA). The Company is not required by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate-to-severe chronic pain.
Rx Drug Compare
Translator
By N2H